FDA approves Phase 3 trial for coronavirus drug

Octapharma announced today that the FDA approved its investigational new drug (IND) application for a Phase 3 clinical trial for its drug therapy in COVID-19 patients.

Octagam 10% [Immune Globulin Intravenous (Human)] therapy will be observed for efficacy and safety in use with COVID-19 patients with severe disease progression, according to a news release.

Get the full story at our sister site, Drug Discovery & Development.

Read more
  • 0